79 related articles for article (PubMed ID: 17379446)
1. A phase I/II trial of topotecan and radiation therapy for brain metastases in patients with solid tumors.
Hedde JP; Neuhaus T; Schüller H; Metzler U; Schmidt-Wolf IG; Kleinschmidt R; Losem C; Lange O; Grohe C; Stier S; Ko YD
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):839-44. PubMed ID: 17379446
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II trial of simultaneous whole-brain irradiation and dose-escalating topotecan for brain metastases.
Kocher M; Eich HT; Semrau R; Güner SA; Müller RP
Strahlenther Onkol; 2005 Jan; 181(1):20-5. PubMed ID: 15660189
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial using patupilone (epothilone B) and concurrent radiotherapy for central nervous system malignancies.
Fogh S; Machtay M; Werner-Wasik M; Curran WJ; Bonanni R; Axelrod R; Andrews D; Dicker AP
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1009-16. PubMed ID: 19879067
[TBL] [Abstract][Full Text] [Related]
4. Topotecan as a radiosensitizer in the treatment of children with malignant diffuse brainstem gliomas: results of a French Society of Paediatric Oncology Phase II Study.
Bernier-Chastagner V; Grill J; Doz F; Bracard S; Gentet JC; Marie-Cardine A; Luporsi E; Margueritte G; Lejars O; Laithier V; Mechinaud F; Millot F; Kalifa C; Chastagner P
Cancer; 2005 Dec; 104(12):2792-7. PubMed ID: 16265674
[TBL] [Abstract][Full Text] [Related]
5. Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases.
Suh JH; Stea B; Nabid A; Kresl JJ; Fortin A; Mercier JP; Senzer N; Chang EL; Boyd AP; Cagnoni PJ; Shaw E
J Clin Oncol; 2006 Jan; 24(1):106-14. PubMed ID: 16314619
[TBL] [Abstract][Full Text] [Related]
6. Effects of concurrent topotecan and radiation on 6-month progression-free survival in the primary treatment of glioblastoma multiforme.
Grabenbauer GG; Gerber KD; Ganslandt O; Richter A; Klautke G; Birkmann J; Meyer M
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):164-9. PubMed ID: 19695435
[TBL] [Abstract][Full Text] [Related]
7. Topotecan in the treatment of brain metastases. A phase II study of GOIM (Gruppo Oncologico dell'Italia Meridionale).
Lorusso V; Galetta D; Giotta F; Rinaldi A; Romito S; Brunetti C; Silvestris N; Colucci G
Anticancer Res; 2006; 26(3B):2259-63. PubMed ID: 16821598
[TBL] [Abstract][Full Text] [Related]
8. Topotecan and cisplatin in combination with concurrent twice-daily chemoradiation in limited disease small cell lung cancer-a Danish Oncological Lung Cancer Group (DOLG) phase II trial.
Sorensen M; Lassen U; Palshof T; Jensen BB; Johansen J; Jensen PB; Langer SW
Lung Cancer; 2008 May; 60(2):252-8. PubMed ID: 18036701
[TBL] [Abstract][Full Text] [Related]
9. A phase 2 trial of whole-brain radiotherapy combined with intravenous chemotherapy in patients with brain metastases from breast cancer.
Cassier PA; Ray-Coquard I; Sunyach MP; Lancry L; Guastalla JP; Ferlay C; Gomez F; Curé H; Lortholary A; Claude L; Blay JY; Bachelot T
Cancer; 2008 Nov; 113(9):2532-8. PubMed ID: 18780315
[TBL] [Abstract][Full Text] [Related]
10. A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer.
Gatcliffe TA; Tewari KS; Shah A; Brewster WR; Burger RA; Kuo JV; Monk BJ
Gynecol Oncol; 2009 Jan; 112(1):85-9. PubMed ID: 18977518
[TBL] [Abstract][Full Text] [Related]
11. Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer (NCCTG 95-20-53).
Schild SE; Bonner JA; Hillman S; Kozelsky TF; Vigliotti AP; Marks RS; Graham DL; Soori GS; Kugler JW; Tenglin RC; Wender DB; Adjei A
J Clin Oncol; 2007 Jul; 25(21):3124-9. PubMed ID: 17634491
[TBL] [Abstract][Full Text] [Related]
12. A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer.
Shah C; Ready N; Perry M; Kirshner J; Gajra A; Neuman N; Garziano S
Lung Cancer; 2007 Jul; 57(1):84-8. PubMed ID: 17399850
[TBL] [Abstract][Full Text] [Related]
13. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer.
Eckardt JR; von Pawel J; Pujol JL; Papai Z; Quoix E; Ardizzoni A; Poulin R; Preston AJ; Dane G; Ross G
J Clin Oncol; 2007 May; 25(15):2086-92. PubMed ID: 17513814
[TBL] [Abstract][Full Text] [Related]
14. Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial.
Mehta MP; Shapiro WR; Phan SC; Gervais R; Carrie C; Chabot P; Patchell RA; Glantz MJ; Recht L; Langer C; Sur RK; Roa WH; Mahe MA; Fortin A; Nieder C; Meyers CA; Smith JA; Miller RA; Renschler MF
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1069-76. PubMed ID: 18977094
[TBL] [Abstract][Full Text] [Related]
15. A phase II evaluation of pentoxifylline combined with radiation in the treatment of brain metastases.
Johnson FE; Harrison BR; McKirgan LW; Raju PI; Roy TK; Virgo KS
Int J Oncol; 1998 Oct; 13(4):801-5. PubMed ID: 9735411
[TBL] [Abstract][Full Text] [Related]
16. Comparison of short-course versus long-course whole-brain radiotherapy in the treatment of brain metastases.
Rades D; Bohlen G; Dunst J; Lohynska R; Veninga T; Stalpers L; Schild SE; Dahm-Daphi J
Strahlenther Onkol; 2008 Jan; 184(1):30-5. PubMed ID: 18188520
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II trial of sequential chemoradiotherapy using a novel hypoxic cell radiosensitizer, doranidazole (PR-350), in patients with locally advanced non-small-cell lung Cancer (WJTOG-0002).
Nishimura Y; Nakagawa K; Takeda K; Tanaka M; Segawa Y; Tsujino K; Negoro S; Fuwa N; Hida T; Kawahara M; Katakami N; Hirokawa K; Yamamoto N; Fukuoka M; Ariyoshi Y
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):786-92. PubMed ID: 17512126
[TBL] [Abstract][Full Text] [Related]
18. A boost in addition to whole-brain radiotherapy improves patient outcome after resection of 1 or 2 brain metastases in recursive partitioning analysis class 1 and 2 patients.
Rades D; Pluemer A; Veninga T; Dunst J; Schild SE
Cancer; 2007 Oct; 110(7):1551-9. PubMed ID: 17654659
[TBL] [Abstract][Full Text] [Related]
19. A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: a Gynecologic Oncology Group study.
Fiorica JV; Blessing JA; Puneky LV; Secord AA; Hoffman JS; Yamada SD; Buekers TE; Bell J; Schilder JM;
Gynecol Oncol; 2009 Nov; 115(2):285-9. PubMed ID: 19726073
[TBL] [Abstract][Full Text] [Related]
20. Phase II clinical trial of whole-brain irradiation plus three-dimensional conformal boost with concurrent topotecan for brain metastases from lung cancer.
Ge XH; Lin Q; Ren XC; Liu YE; Chen XJ; Wang DY; Wang YQ; Cao B; Li ZG; Liu ML
Radiat Oncol; 2013 Oct; 8():238. PubMed ID: 24125485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
